Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole

AUTOR(ES)

Fernández, Marisa Liliana, Marson, Maria Elena, Ramirez, Juan Carlos, Mastrantonio, Guido, Schijman, Alejandro Gabriel, Altcheh, Jaime, Riarte, Adelina Rosa, Bournissen, Facundo García

FONTE

Mem. Inst. Oswaldo Cruz

DATA DE PUBLICAÇÃO

15/03/2016

RESUMO

Pharmacological treatment of Chagas disease with benznidazole (BNZ) is effective in children in all stages, but it is controversial in chronically infected adults. We report the pharmacokinetics and pharmacodynamics in six adult patients with Chagas disease treated with the new BNZ formulation (ABARAX®) in doses between 2.5-5.5 mg/Kg/day. All but one patient had plasmatic BNZ concentrations within the expected range. All patients finalised treatment with nondetectable Trypanosoma cruziquantitative polymerase chain reaction, which remained nondetectable at the six month follow-up. Our data suggests parasitological responses with the new BNZ and supports the hypothesis that treatment protocols with lower BNZ doses may be effective.

Documentos Relacionados

• Serological based monitoring of a cohort of patients with chronic Chagas disease treated with benznidazole in a highly endemic area of northern Argentina
• A serological, parasitological and clinical evaluation of untreated Chagas disease patients and those treated with benznidazole before and thirteen years after intervention
• Pharmacotherapeutic follow-up of patients with Chagas disease using benznidazole: drug-related problems and pharmaceutical interventions
• Novel Pharmacokinetic-Pharmacodynamic Model for Prediction of Outcomes with an Extended-Release Formulation of Ciprofloxacin
• The role of benznidazole with cyanocobalamin and ascorbic acid in treating the chronic phase of Chagas disease